As we count down the handful of trading days left until July 31 when the Fed makes their decision to or not to make their first interest rate reduction in 10 years, the markets today were overwhelmingly positive and “technologically driven” by some of the name brand tech and so-called FANG stocks. However, the little guys on the Russell 2000 overall did not come to play. The Dow gained 17.70 points today closing up .07% closing at 27,171.90. The S&P 500 added 8.42 points or .28% closing at 2985.03 but still under the 3000 level. The tech-heavy Nasdaq closed at 8,204.14 up .71% while adding 57.65 points. The Russell 2000, the small-cap stock market index representing the bottom 2,000 stocks in the Russell 3000 Index as mentioned did participate in the positive upswing as it declined 3.11 points closing at 1,544.78 down .20%.
Some of the big tech stocks that led the markets finished the day accordingly. Apple (AAPL) was up strongly rising 2.29% closing at $207.22/share & Amazon (AMZN) also gained 1.07% closing at 1,985.632. Alphabet (GOOG) hopped forward .71% closing at $1,138.07.08 & Facebook (FB) grabbed their 2% closing at $202.32. Shares of Microsoft (MSFT) closed trading at $138.43 rising 1.32%. Chipmaker Intel (INTC) moved sharply higher up 2.15% closing at $51.35/share & Micron (MU) won a whopping 3.67% today closing at $47.19/share. Nvidia (NVDA) chipped in for 1.71% gain closing at $171.32/share. Netflix (NFLX) however was closed lower by 1.42% ending at $310.62/share. NYC-based Yext (YEXT), an innovator in search giving customers control over their business information across the digital landscape, closed at $20.59/share flat for the day.
Oil prices stepped higher by 1% closing at $56.20/bbl. Dow 30 energy participants Chevron (CVX) moved higher by .22% closing at $125.31 & Exxon (XOM) closed higher by .11% closing at $75.07.
Gold closed lower at $1418.20/oz. Silver closed at $16.23/oz. Hecla Mining Company (HL) closed at higher today at $1.96/share up 3.70%. First Majestic Silver (AG) closed at higher again too $10.10/share up 2.02% and reached a 52-wk high of $10.30.
Financials/Money Management Sector
Institutional alternative asset manager Och-Ziff Capital Management Group (OZM) closed at $23.06/share up 1.10% or $..25/share closing off its recently minted new 52-wk high of $25.49. The 52-wk range is $8.60 – $25.49. OZM sports a 4.35% cash dividend.
Los Angeles-based Colony Capital (CLNY) a leading global investment management firm with assets under management of $43 billion closed at $5.10 up 1.59% after hitting an intraday high of $5.12. CLNY pays an 8.76% cash dividend.
Goldman Sachs (GS) closed at $214.00 up .22%.
JP Morgan (JPM) closed at $114.27 up .64%.
Consumer Goods & Entertainment
The Home Depot (HD) closed at $211.27/share losing .83%.
The Walt Disney Company (DIS) closed trading up .71% at $140.84/share after breaking yet another box office record raking in $185 million for the “The Lion King” making it the highest opening for a film in July.
Nike (NKE) closed at $85.97off .97%. Nike recently missed analyst earnings estimates but maintained full-year guidance.
Walmart (WMT) closed at $112.95 down .19%.
The healthcare sector moved lower today. The S&P 500 healthcare sector closed at 1059.39 down .15%. UnitedHealth (UNH) closed lower down .52% closing at $255.32, Walgreens Boots Alliance (WBA) closed at $53.94/share off .92% & Cigna (CI) fell 1.77% closing at $170.61.
Johnson & Johnson (JNJ) reported earnings recently beating analyst expectations as they confirmed a +40% increase in Q2 net income year over year. JNJ shares closed at $128.64 down 1.28% today. They are still dealing with the overhang of the opioid & mesothelioma related issues which are making the headlines daily.
INVO Bioscience, Inc. (IVOB) ended the day at $.34/share as daily trading volume continues to rise in concert with their announcing progress after their exclusive U.S. partnership with Ferring Pharmaceuticals, a leader in the reproductive health industry was announced in Q1-2019. Ferring has committed to providing the necessary sales and marketing resources to more fully develop the market in the United States. There are countless couples not able to receive reproductive treatments today, and Ferring can be instrumental in addressing the unmet needs of this cohort. Ferring has the industry experience, relationships and the marketing capabilities to successfully embed the INVOcell in clinics throughout the country. IVOB is a medical device company, headquartered in Sarasota, FL focused on creating simplified, lower-cost treatment options for patients diagnosed with infertility. The company’s lead product, the INVOcell, is a novel medical device used in infertility treatment that is FDA cleared and that enables egg fertilization and early embryo development in the woman’s vaginal cavity. IVOB also announced last week news of their recent appointment of Pressly Ahammed as the new Director of International Business Development and he will be responsible for the Company’s international distribution channels in Europe, Middle East, Africa & parts of Asia. Ahammed joined IVOB from Cooper Surgical where he held a similar position. See complete story.
Corindus Vascular Robotics, Inc. (NYSE American: CVRS) CVRS closed trading at $2.79/share up 4.49% today and their 52-week trading range is $.78- $3.49/share. CVRS is a leading developer of precision vascular robotics, announced recently that Albert Einstein Jewish Hospital (Hospital Israelita Albert Einstein) in São Paulo, Brazil has become the first hospital in the Southern Hemisphere to implement Corindus’ CorPath GRX System. Ranked as the best hospital in Latin America for 10 years in a row, Albert Einstein Jewish Hospital will continue to uphold its standing by leveraging the Company’s technology in its health system’s leading research facilities. The Company’s CorPath® platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. For additional information, visit www.corindus.com CVRS shares closed at $2.62/share and the 52-week trading range is $.78- $3.49/share. Corindus is due to report earnings July 30 time frame according to etrade.com.
The Ishares Nasdaq Biotechnology ETF (IBB) gained .23% closing at $105.12. This sector has been on a more than healthy run over the last 30 days. The 52-wk range is $89.01 – $122.97.
Pfizer (PFE) closed higher at $42.82 up .12%. The recently announced their acquisition of Array BioPharma (ARRY) for ~$11.4 billion or $48/share in cash. See complete story. The pharmaceutical giant and Dow component Merck & Co, Inc. (MRK) that recently announced the acquisition of Tilos Therapeutics for a consideration of up to $773 million closed at $81.21 down by .22%.
Atossa Genetics (ATOS), a Seattle-based biotech firm developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions closed at $2.04 flat on the day. The average daily trading volume is 809,115 shares per day. Atossa recently announced that it is developing a new proprietary modified-release oral tablet form of its Endoxifen, which is the form of the drug that the company intends for future clinical studies and commercialization. This is the next generation of oral Endoxifen following the successful clinical studies of the capsule form of the company’s oral Endoxifen. A patent application covering the new table has also been filed with the U.S. Patent and Trademark Office. As part of the development of this new oral tablet, Atossa has commenced a Phase 1 study in Australia to ascertain the pharmacokinetics of the tablet. The study is randomized, double-blinded and placebo-controlled with both single and multiple-doses in 2 groups with a total of 24 healthy female volunteers who will be dosed for 14 days. Atossa’s oral Endoxifen capsule, which has been used in previous clinical studies, will serve as the comparator. The first group of the study has now been enrolled and dosed. Steven C. Quay, Ph.D., M.D., CEO, and president of Atossa, commented: “We are excited to take this next step in our oral Endoxifen product development. Based on the abundance of information from our previous clinical studies, we strongly believe in the potential efficacy of oral dosing and intend for this modified-release tablet to be the commercial form of our oral Endoxifen. The goal of the modified-release aspect of the drug is to create more even uptake of the drug which we believe may reduce side effects and improve efficacy. This new study builds on the success of our Phase 1 studies of the oral capsule and topical forms of our Endoxifen, our recent successful Phase 2 study of topical Endoxifen, which demonstrated significant efficacy in reducing breast density, and our single-patient compassionate use study of oral Endoxifen. Following the completion of this Phase 1 trial, we will continue to use this proprietary modified-release formulation for future clinical studies — including a Phase 2 trial that we have already indicated is in development — and ultimately regulatory approval. We look forward to completing the study in the next quarter.”
San Diego-based biotech Fate Therapeutics (NASDAQ: FATE), dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, closed up at $22.48/share up 5.19% on 667,990 shares of trading near at $22.80 near its new all-time intraday high of $22.82 that they established last week! The 52-week range is $8.64 – $22.82. Cantor Fitzgerald initiated coverage today, July 22nd, with an overweight rating. Oppenheimer initiated coverage on Friday, July 12th with an Outperform Rating. Guggenheim Securities initiated coverage on FATE last week with a “Buy Rating” and a $25/share price target. Mizuho initiated coverage with a price target of $27/share recently.
Bedford, Massachusetts-based Stoke Therapeutics is a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. Recently Stoke Therapeutics announced the pricing of its initial public offering (IPO) of 7,891,110 shares of its common stock at a price to the public of $18.00 per share. The shares are now trading on The Nasdaq Global Select Market as of June 19, 20,19 under the symbol “STOK.” Stoke’s stock traded as high as $31.76 recently a new all-time high prior to closing trading at $23/share 1.92% today. See complete story.
Xeris Pharmacueticals, Inc. (XERS) closed up 4.23% at $12.80. Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations.
Elsewhere on the recent IPO front, Zoom Video Communications (ZM) moved higher by 3.52% closing at $96.67 & Uber Technologies (UBER), the ride-sharing company closed higher by 1.18% at $43.69/share & still below its recent IPO price of $45. Plant-based burger maker Beyond Meat (BYND) continues to defy gravity moving sharply higher closing at $196.20 up an amazing 9.85% almost reaching its all-time high of $201.88 intraday trading. Their meat is made of four main ingredients: water, pea protein isolate, canola oil & refined coconut oil and is meant to taste like “meat. Slack Technologies (WORK) which jumped into the public markets with their IPO last week flying up 48.5% from their offering price of $26/share & closed today at $33.25 up nicely by 6.23%. Slack is a provider of a cloud-based workplace messaging app and went public via a direct listing avoiding paying fees to the relevant banks.
No data points to share from the economy today but stay tuned!
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!